Sector News

Actelion CEO says has received no takeover approaches

October 21, 2014
Life sciences
(Reuters) – Actelion has received no takeover bids from interested parties, the company’s chief executive said on Tuesday.
 
Analysts have in the past touted Actelion as a potential takeover target, since its healthy pipeline drugs to treat pulmonary arterial hypertension could draw U.S. bidders seeking to lower their tax bill by moving their tax base to Switzerland, a tactic known as inversion.
 
But last month’s rule changes by the U.S. Treasury Department aimed at curtailing such deals has prompted several pharmaceutical companies, including AbbVie, to ditch original M&A plans.
 
Asked by Reuters whether Actelion has been approached by any interested parties, the company’s Chief Executive Jean-Paul Clozel said, “No.”
 
Speaking after Actelion published third-quarter results that beat expectations, Clozel said the biotech firm wanted to increase shareholder returns and grow ahead of the market at the same time.
 
(Reporting by Caroline Copley)

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach